Modern Medical Device Regulation: Volume 5: Evidence, Economics, and U.S. Market Reimbursement

Volume 5 of the Modern Medical Device Regulation series--Evidence, Economics, and U.S. Market Reimbursement--examines the often overlooked governance layer of reimbursement that ultimately determines whether medical technologies reach patients.. While regulatory approval is commonly viewed as the gateway to market entry, real-world adoption in the United States is frequently governed by a second equally powerful system--coverage, coding, and payment decisions led by the Centers for Medicare & Medicaid Services (CMS) and the broader reimbursement ecosystem. This volume explores how evidence generation, health economics, and reimbursement strategy must operate as an integrated component of the medical device total product lifecycle (TPLC). Manufacturers who treat reimbursement as a downstream administrative step often discover too late that satisfying regulatory authorization requirements does not guarantee clinical adoption, hospital purchasing, or patient access. Through two integrated chapters, the book examines: Integrated Evidence Strategy: How health economics and outcomes research (HEOR) must be embedded alongside regulatory compliance, clinical evidence, and lifecycle risk management. The Hidden Half of U.S. Market Entry: Why CMS policy and reimbursement frameworks frequently determine the real-world success of medical technologies. Evidence as Access: How value demonstration, comparative outcomes, and economic modeling shape coverage and payment decisions. Evidence determines not only market access but also the continued retention of medical technology within healthcare systems. Lifecycle Governance: Aligning regulatory, clinical, and reimbursement strategy across product development and commercialization. This premium upgraded edition expands and refines the original volume with enhanced strategic framing, stronger lifecycle integration, and added interpretive material connecting regulatory evidence, health economics, and reimbursement governance. Rather than treating reimbursement as a separate discipline, this volume presents it as a core governance structure influencing technology adoption across hospitals, health systems, and national healthcare programs. As healthcare systems become more technologically complex, the central challenge is not the sophistication of devices themselves, but the fragmentation of the systems that evaluate and adopt them. "To improve the level of hospital quality, we should not fear complex devices, but disconnected systems." For regulatory professionals, health economists, clinical engineers, policy analysts, healthcare technology leaders and educators, this volume provides a strategic framework for understanding how evidence, economics, and reimbursement interact to determine whether innovation ultimately reaches the patient.